Janney Montgomery Scott LLC Alkermes Plc. Transaction History

Janney Montgomery Scott LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$23.01 - $28.55 $220,228 - $273,252	-9,571 Reduced 30.74%	21,561 $603,000
Q2 2024 Jul 25, 2024	BUY	$23.21 - $27.24 $17,662 - $20,729	761 Added 2.51%	31,132 $750,000
Q1 2024 May 01, 2024	SELL	$26.4 - $32.56 $80,229 - $98,949	-3,039 Reduced 9.1%	30,371 $822,000
Q4 2023 Feb 07, 2024	BUY	$23.37 - $28.68 $780,791 - $958,198	33,410 New	33,410 $927,000
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $448,190 - $520,555	-9,398 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$49.16 - $54.45 $462,005 - $511,721	9,398	9,398 $478,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.84B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

Stay updated on Janney Montgomery Scott LLC with notifications on news.